Bionomics' technology involves a suite of integrated synthetic methods that gives access to complex drug-like molecules. Many marketed drugs and naturally occurring bioactive molecules have complex ring structures. While the importance of this type of structure is recognized, these complex molecules are often too difficult to synthesize for drug discovery purposes. Bionomics is able to produce focused compound libraries in this complex molecular space. These libraries have the advantage of being focused on the target of interest and being weighted towards drug-like characteristics. In addition, the synthesis technology is scalable for commercial production.

By facilitating combinatorial development around complex drug-like molecules, Bionomics is able to create new patentable molecules that can improve on pre-existing drug leads and that can be synthesised in fewer steps, reducing the cost of manufacture.